Medical Xpress October 11, 2024
MiMedx, a Marietta, Georgia, biomedical company that makes skin grafts and other treatments, is entangled in contentious legal battles with filings in recent weeks by a federal government agency in one court and 10 former employees in another.
Near the center of both conflicts is a new wound treatment it calls Axiofill, which the Food and Drug Administration said in a warning letter MiMedx is not authorized to sell, and which the company continues to market while it challenges that determination in federal court. The former employees, meanwhile, allege in a labor dispute they were forced to sell the product.
In statements to The Atlanta Journal-Constitution, the company defended the sale of the product and alleged the ex-employees broke agreements...
Today's Sponsors
Today's Sponsor